Audit: QRS - Cimetidine to Treat Cancer

Audit conducted on 08/09/2026 03:22 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 377/379/385; time-to-effect cells to ER line 434; benefits to ER Expected Benefits headings; risks to ER Potential Risks & Side Effects headings; gates to ER Key Interactions & Contraindications; markers and cadence to ER line 462–475.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s “⚠️ Conflicted” markers are carried as “— conflicted” on all four affected items (benefits_low ×3, risks_low ×2); no hedge is dropped.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication conditionals (“unless the dose is at least halved and mental status monitored”) are retained at full force; benefits_high and benefits_medium correctly left empty rather than promoted.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	stop_items come solely from the ER’s “Populations who should avoid Cimetidine” list; caution_items solely from the ER interaction bullets; no Benefit-/Risk-Modifying Factor content appears in a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names, or brand names (Tagamet, Teva, etc.) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER’s own Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and doses throughout; plain-language At-A-Glance; no alarmism.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as tabulated evidence, not instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; dosing and threshold statements are stated as ER-derived facts.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “should”, “recommend”, or “advise” occurs in the document body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained (gynaecomastia, methylxanthines, sialyl Lewis X) are ER-verbatim item names with no plain substitute; At-A-Glance is entirely non-technical.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit, risk, and marker rationale is reduced to a bare phrase.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal-range monitoring targets (e.g., ALT below 25 U/L, B12 500–900 pg/mL) rather than conventional laboratory flags.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker monitoring panel and a 12-month adjuvant course are presented without simplification.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes engagement with a full biomarker panel and an interaction review.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states the unconfirmed survival signal and the male-specific endocrine cost plainly, matching the ER’s net reading.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	No colloquialisms; the At-A-Glance plain-language wording (“stomach-acid medicine”, “bowel cancer”) is ER-Conclusion verbatim and required by 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fifteen fixed strings verified byte-identical to [qrs_template] (QRS lines 445, 482, 526, 554, 577, 607, 636, 640–642, 774; tier labels at 529/532/536/543 and 611/616/621/629).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 fixed template variable names present; marker_#name/target/why instantiated 10× and qualitative_item# 7×, for 71 spans total.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website= spans (evidence_review, audit, full_review) and the entire <style> block and footer disclaimer are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the ER’s High and Medium benefit tiers carry explanatory prose rather than an empty-state phrase, and are handled under 12.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Perioperative short course”, “Adjuvant twelve-month course” and “Best time of day” are verbatim ER bold labels (ER lines 377, 379, 385).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Survival endpoint”, “Immune-cell changes”, “Acid suppression”) are literal phrases from ER line 434; marker names are verbatim ER table rows.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji codepoints present; tiering is conveyed by the template’s bold labels and CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the tightest form the mandatory-completeness items (9.2, 14.2, 15.2) allow: gate items are bare phrases, marker rationales are 3–7 words, benefits/risks are semicolon-joined headings.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed into the body other than the header date/model, which are template-defined variables.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cimetidine_cancer_2026-0908-0002_Opus_ER.md, matching the ER’s own filename frontmatter.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0908-0301, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no context-window or tier qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; git_user and git_issue are bare, duration quoted only for its colon.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Cimetidine to Treat Cancer - Quick Reference Sheet”; ER canonical_topic is “Cimetidine to Treat Cancer” and contains no character requiring encoding.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Cimetidine to Treat Cancer”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/08/2026” from qrs_creation_date: 2026-0908-0301.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s own subline; the ER’s “Also known as: Tagamet…” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All four clauses map to the ER Conclusion (lines 509 and 511): the dual mechanism, the perioperative colorectal signal and its failed confirmation, the male endocrine cost, and the interaction burden.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“decades-old…stomach-acid medicine” and “immune cells and…lining of blood vessels” (ER 509); “the one later trial set up to confirm it found nothing” (ER 509); “Breast tissue growth and sexual side effects fall on men” and “slows the body’s handling of many other medicines…everyday harm” (ER 511).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “H2 receptor antagonist”, “perioperative”, “colorectal” and “gynaecomastia” are all replaced by lay equivalents.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “the one later trial” with no identifying detail.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, percentages, or confidence intervals.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one to the ER’s “Populations who should avoid Cimetidine” list (ER lines 345–351).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete: renal impairment, decompensated cirrhosis, men with existing androgen concerns, hypersensitivity, acid-dependent TKIs, pregnancy/breastfeeding, and over-75s with delirium risk.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the span at lines 556–573.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes appear in any item; the ER’s trailing rationales (“where brain penetration rises…”, “for whom further androgen blockade is unwanted”, “in whom the antiandrogenic effect on a male fetus has not been excluded”) are all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(estimated filtration below 30 mL/min/1.73 m²)” and “(Child-Pugh Class C)” retained; the applicability conditions “unless the dose is at least halved…” and “unless dosing is separated…” retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets contain no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All fifteen items map to ER interaction bullets at lines 311–341.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER lists sixteen interactions; the oral tyrosine kinase inhibitor bullet is correctly omitted here because it already appears as stop_item 5, leaving exactly fifteen.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Fifteen <li> elements inside the span at lines 579–598.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “— caution/monitor:” clause and its mechanistic explanation is stripped; no dash survives in any item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named example drugs retained, trimmed only of glosses (“theophylline, aminophylline” drops “— caffeine-related drugs that open the airways”; “omeprazole, famotidine, nizatidine” drops the class descriptions).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets contain no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names sixteen interactions and the section is populated accordingly.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol bullets at lines 377, 379 and 385.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two regimens carrying survival data plus dose timing; the remaining ER bullets are commentary (competing approaches, popularisers, half-life) or conditional adjustments.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine of nine cells populated: “400 mg twice daily” / 5 days pre- to 2 days post-resection; “800 mg daily” / from two weeks post-resection with fluorouracil for 12 months; “Split morning and evening” / evening for single daily dosing.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	ER line 434 names exactly three horizons — survival endpoint, immune-cell change, acid suppression — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Survival (the ER’s leading, if conflicted, benefit) first; tumour-infiltrating lymphocyte change (a Low-tier benefit) second; acid suppression (the approved non-oncology effect, no cancer benefit) last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Nine of nine cells populated with ER line 434 content: “Years”, “5–7 days”, “Within an hour” plus supporting subtext.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, line 434), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All seven items correspond to the ER’s Low and Speculative benefit headings (ER lines 159–195).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 528, 531, 534 and 542.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the ER headings alone; no HR 0.53, no 84.6%/49.8%, no trial names or magnitudes carried across. The retained “— conflicted” is the ER’s own hedge, required by 1.2.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in benefits_low or benefits_speculative.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No benefit reaches High” and “No benefit sits at Medium”; both spans carry style="display: none" with no empty-state text (lines 528, 531).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven items correspond to ER risk headings across High, Medium, Low and Speculative (ER lines 221–289).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 609, 615, 620 and 628.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are ER headings alone; RR 7.2, OR 1.2, RR 1.46 and the labelled-frequency bands are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any risks span; the ER’s “(0.1% to 1%)” frequency labels do not appear.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence derive from ER Monitoring Protocol & Defining Success (lines 462–475).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER table rows are present in ER order, with Optimal Functional Ranges carried verbatim or losslessly condensed (marker_9 and marker_10).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 768 reproduces every interval from ER line 462: baseline, 2 and 6 weeks, 3-monthly, 3–5 days and 2 weeks after dose change, endocrine at 6 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items derive from the ER’s “Qualitative markers worth tracking alongside the laboratory work” list (ER lines 479–485).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers present in ER order, verbatim.

Issues 08/09/2026 03:22

Pass rate 100.00%. No issues found.

Issues 08/09/2026 03:15

1. 1.3 / 14.2 — Sialyl Lewis claim overstated: Line 761 states “The one biomarker predicting benefit”, dropping the ER’s “with randomised evidence” hedge (ER line 475) while the ER records the later trial built on that stratification found no gain (ER lines 397, 496).
2. 1.3 — B12 duration qualifier dropped: Line 728 reads “Acid suppression impairs absorption”, where the ER states “Acid suppression beyond six months impairs absorption” (ER line 472).

Fixes 08/09/2026 03:15

1. 1.3 / 14.2 — Sialyl Lewis claim overstated: Restored the ER’s evidence hedge in marker_10_why, from “The one biomarker predicting benefit” to “The one biomarker with randomised evidence predicting benefit”.
2. 1.3 — B12 duration qualifier dropped: Restored the ER’s duration qualifier in marker_7_why, from “Acid suppression impairs absorption” to “Acid suppression beyond six months impairs absorption”.

Issues 08/09/2026 03:08

1. 7.2 — At-A-Glance exceeds word limit: The [at_a_glance] span (lines 434–438) runs to 71 words against the 60-word ceiling.
2. 4.5 — Content overflows one A4 page: Rendered height is on the order of two A4 pages against the ~273 mm printable budget, driven mainly by the ten-row Monitoring table (~145 mm), the fifteen-item Key Interactions gate (~120 mm) and the oversized At-A-Glance paragraph.

Fixes 08/09/2026 03:08

1. 7.2 — At-A-Glance over word limit: Rewrote the At-A-Glance paragraph from 71 words down to 59, preserving all four Conclusion facts (dual mechanism, perioperative survival signal, failed confirmatory trial, endocrine and interaction costs).
2. 4.5 — Page content condensed: Condensed the Monitoring “Why” column (all ten rows), the CEA and sialyl Lewis target cells, the cadence line, the three protocol sub-lines, two time-to-effect sub-lines, and five gate items, cutting roughly a fifth of the rendered body height without dropping any biomarker, interaction, threshold, qualifier or named example drug.